Elicio company information, Employees & Contact Information

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma Elicio Therapeutics

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial Elicio Therapeutics

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Elicio Therapeutics

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients Elicio Therapeutics

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Elicio Therapeutics

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates Elicio Therapeutics

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy Elicio Therapeutics

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 Elicio Therapeutics

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment Elicio Therapeutics

Elicio Therapeutics Reports Inducement Grants GlobeNewswire

Elicio Therapeutics Secures $10 Million in Financing GlobeNewswire

Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher Yahoo Finance

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting Elicio Therapeutics

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit Elicio Therapeutics

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer Elicio Therapeutics

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer Elicio Therapeutics

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Elicio Therapeutics

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines Elicio Therapeutics

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering Elicio Therapeutics

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P Elicio Therapeutics

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors Elicio Therapeutics

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 Elicio Therapeutics

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note Elicio Therapeutics

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting Elicio Therapeutics

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium Elicio Therapeutics

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting Elicio Therapeutics

Elicio Therapeutics Announces $6.0 Million Private Placement Financing Elicio Therapeutics

Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors Elicio Therapeutics

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study Elicio Therapeutics

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting Elicio Therapeutics

Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors Elicio Therapeutics

Elicio Therapeutics Announces Completion of Merger with Angion Biomedica Elicio Therapeutics

Joy Seymour Elicio Therapeutics

Elicio Therapeutics Moves into Boston’s Seaport District and Provides Update on Programs Elicio Therapeutics

Interview with Peter Goderis, Elicio, and Felipe Cornago, BayWa r.e. WindEurope

Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 Yahoo Finance

Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move Fierce Biotech

Cancer Vaccine Developer Elicio Therapeutics Awards Stock Options to Expand Research Team Stock Titan

Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data Seeking Alpha

Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica BioSpace

France: Total, Ørsted and Elicio join forces to bid for a wind farm offshore Dunkirk TotalEnergies.com

Elicio Therapeutics and Angion Enter into Definitive Merger Agreement GlobeNewswire

Ørsted, Total and Elicio join forces to bid for offshore wind farm by Dunkirk, France Orsted

New Mexico Amber Alert: Elicio Platero missing from Valencia County BNO News